Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

le Gottlieb, Alice B, Strand, Vibeke, Kishimoto, Mitsumasa, Mease, Philip, Thaçi, Diamant, Birt, Julie, Lee, Chin H, Shuler, Catherine L, Lin, Chen-Yen, Gladman, Dafna D
Foilsithe in Rheumatology (Oxford) (2018)

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, doub...

le Mease, Philip J, van der Heijde, Désirée, Ritchlin, Christopher T, Okada, Masato, Cuchacovich, Raquel S, Shuler, Catherine L, Lin, Chen-Yen, Braun, Daniel K, Lee, Chin H, Gladman, Dafna D
Foilsithe in Ann Rheum Dis (2017)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

le Keystone, Edward C, Taylor, Peter C, Drescher, Edit, Schlichting, Douglas E, Beattie, Scott D, Berclaz, Pierre-Yves, Lee, Chin H, Fidelus-Gort, Rosanne K, Luchi, Monica E, Rooney, Terence P, Macias, William L, Genovese, Mark C
Foilsithe in Ann Rheum Dis (2015)